Intra-Abdominal Infection
1 original drugsIntra-Abdominal Infection has 1 FDA-approved novel treatment, led by GE HEALTHCARE across 2 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Intra-Abdominal Infection Market Leaders
Companies with the most FDA-approved novel Intra-Abdominal Infection drugs.
Intra-Abdominal Infection Treatments by Mechanism
Top 2 mechanisms across 2 industry trials with a known mechanism of action.
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Intra-Abdominal Infection Clinical Pipeline by Phase
4 industry-sponsored trials across 3 sponsors
Novel Intra-Abdominal Infection Drugs by Company (New molecular entities)
1 company has an FDA-approved novel drug for Intra-Abdominal Infection.
Reformulations (5 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Intra-Abdominal Infection Drug Targets
Molecular targets of approved and investigational Intra-Abdominal Infection drugs — 2 targets tracked.
Generic Drugs (7 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs